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Abstract 
Triple quadrupole mass spectrometers coupled with high performance liquid chromatography are 
workhorses in quantitative bioanalyses. It provides substantial benefits including reproducibility, 
sensitivity and selectivity for trace analysis. Selected Reaction Monitoring allows targeted assay 
development but data sets generated contain very limited information. Data mining and analysis 
of non-targeted high-resolution mass spectrometry profiles of biological samples offer the 
opportunity to perform more exhaustive assessments, including quantitative and qualitative 
analysis. The objectives of this study was to test method precision and accuracy, statistically 
compare bupivacaine drug concentration in real study samples and verify if high resolution and 
accurate mass data collected in scan mode can actually permit retrospective data analysis, more 
specifically, extract metabolite related information. The precision and accuracy data presented 
using both instruments provided equivalent results. Overall, the accuracy was ranging from 106.2 
to 113.2% and the precision observed was from 1.0 to 3.7%. Statistical comparisons using a 
linear regression between both methods reveal a coefficient of determination (R2) of 0.9996 and a 
slope of 1.02 demonstrating a very strong correlation between both methods. Individual sample 
comparison showed differences from -4.5% to 1.6% well within the accepted analytical error. 
Moreover, post acquisition extracted ion chromatograms at m/z 233.1648 ± 5 ppm (M-56) and 
m/z 305.2224 ± 5 ppm (M+16) revealed the presence of desbutyl-bupivacaine and three distinct 
hydroxylated bupivacaine metabolites. Post acquisition analysis allowed us to produce semi-
quantitative evaluations of the concentration-time profiles for bupicavaine metabolites. 
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Introduction 
Drug discovery and development requires analytical methods that can provide comprehensive 
qualitative exploration, rapid profiling, and high precision and accuracy quantitation [Kaufmann 
et al., 2015; Ramanathan et al., 2011]. The objective is to provide faster, comprehensive and 
more accurate answers to many different questions imbedded in the drug discovery and 
development process [Pritchard et al., 2003]. This is intimately related to our capacity to explore 
complex biological samples with greater depth. For two decades now, most bioanalytical 
methods relied on unit mass resolution mass spectrometers (i.e. Triple Quadrupole and Hybrid 
Quadrupole Linear Ion Trap mass spectrometers) [Ramanathan et al., 2011]. Liquid 
chromatography attached to tandem mass spectrometry (HPLC-MS/MS) has revolutionized the 
analysis of drug and metabolites in complex biological matrices [Lee and Kerns, 1999]. This 
technique replaced older instruments, where less selective detectors were used (e.g. ultraviolet, 
fluorescence, electrochemical). The significant improvement in selectivity led to less matrix 
related interferences and consequently improved signal to noise ratio and reduced analytical error 
[Cairns, 2011; Shrivastava and Gupta 2011, Mulvana, 2010]. Many significant benefits where 
obtained with the adoption of HPLC-MS/MS and users accepted limitations associated with 
selected reaction monitoring methods (SRM). 
High resolution quantitative and qualitative analysis in drug discovery and development may 
provide a wider range of applications compared to traditional analysis performed on unit mass 
resolution instruments (i.e. Triple Quadrupole and Hybrid Quadrupole Linear Ion Trap mass 
spectrometers) [Ma and Chowdhury, 2013; Wagner et al., 2013]. Non-targeted pharmaceutical 
drug analyses using a linear ion trap high-resolution mass spectrometer (LTQ-Orbitrap) was 
recently investigated and the authors shown the system capability for quantitative and qualitative 
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analysis performed in a single experiment [Zhang et al., 2009]. However, the authors used a 
relatively low-resolution setting for the Orbitrap instrument (i.e. 15,000 FWHM) most likely due 
inadequate scan rate for quantitative analysis. During the development of a bioanalytical method, 
it is important to recognize that a detection system needs to satisfy several conditions; primarily, 
it must be sensitive and specific to allow the analysis of trace amounts [Tamvakopoulos, 2007]. 
The analytical methods need to allow the quantitative determination and comparisons of drug, 
metabolites or other molecules among samples by simultaneous or sequential detection with 
acceptable figure of merits [Ye et al., 2009]. The analytical strategy used in bioanalysis needs to 
minimize the fluctuation in data measurements that might mask or reduce the precision of the 
determinations and consequently reduce the sensitivity of the assay [Cairns, 2011]. It is well 
known that technical and instrumental errors can be a significant source of variation [Friedman, 
2012; Shrivastava and Gupta 2011, Mulvana, 2010]. Thus, the analytical strategy used may 
hamper the ability to adequately determine drug and metabolite concentrations in biological 
matrices for further analysis (e.g. pharmacokinetics and toxicokinetics). The quantitative 
performance of Triple Quadrupole (QqQ) and Hybrid Quadrupole Linear Ion Trap (QqLIT) mass 
spectrometers instruments are very well established. However, high resolution mass spectrometer, 
such as a hybrid Quadrupole-Orbitrap mass spectrometer is generally not used for routine 
quantitative drug and metabolites analysis despite offering major advantages in mass resolution 
(up to 280,000 FWHM) and mass accuracy (< 2 ppm). These figures of merit can provide 
substantial analytical advantages for qualitative analysis [Backfisch et al., 2014; Dinger et al., 
2014; Wohlfarth et al. 2013]. However it is important to adequately test the precision and 
accuracy and compare it with a more traditional approach [Yoneyama et al. 2014]. One major 
issue with Orbitrap instruments was associated with slow scan rate at higher resolution setting 
resulting in fewer data point being collected. This was a significant source of data variation 
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affecting quantification. Newer Orbitrap instruments present improve scan rate at high-resolution 
settings allowing, possibly, significant improvement. In our case, we compared results generated 
with a state of the art Thermo Scientific TSQ Quantiva Triple Quadrupole Mass Spectrometer 
(QqQ) with a Thermo Scientific Q-Exactive Plus Orbitrap Mass Spectrometer operating at a 
resolution of 70,000 FWHM. The objectives of this study was to (1) test method precision and 
accuracy, (2) statistically compare bupivacaine drug concentration in real study samples and (3) 
verify if operating in scan mode at high resolution (HR) and accurate mass (AM) can actually 
permit retrospective data analysis, more specifically, extract metabolite related information.  
Materials and Methods 
Chemicals and Reagents 
Bupivacaine was obtained from Galenova (St-Hyacinthe, Canada) as a USP standard. d9-
Bupivacaine was obtained from Toronto Research Chemicals (Toronto, Canada). Methanol, 
acetonitrile, formic acid and water were purchased from Fisher Scientific (NJ, USA). Ten mL of 
cat plasma was obtained from the Faculté de médecine vétérinaire de l'Université de Montréal 
donor group to perform method evaluations.  
Plasma sample preparation 
Using a protein precipitation as sample preparation technique, bupivacaine was extracted from 
cat plasma. Five hundred µL of internal standard solution (5.0 ng/mL of d9-bupivacaine in 
methanol) was added to an aliquot of 25µL of plasma sample. The sample was vortexed for 
approximately 5 seconds and let stand for a period of 10 minutes, then centrifuged at 12,000 g for 
10 minutes.  The supernatant was transferred to an injection vial for analysis. 
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Chromatographic conditions 
An isocratic mobile phase was used with a Thermo Scientific Aquasil C18 column (100 x 2.1 mm 
I.D., 5 µm) heated at 40°C. The mobile phase conditions consisted of acetonitrile and 10 mM 
ammonium formate in type 1 water (pH 3.0) at a ratio of 40:60, respectively. The flow rate was 
fixed at 300 µL/min and bupivacaine and its internal standard eluted at 2.0 minutes. Two µL of 
the extracted sample was injected and the total run time was set at 3.0 minutes. 
Mass spectrometric conditions 
The Thermo Scientific TSQ Quantiva Triple Quadrupole mass spectrometer (San Jose, CA, 
USA) was interfaced with the Thermo Scientific UltiMate 3000 XRS UHPLC system (San Jose, 
CA, USA) using a pneumatic assisted heated electrospray ion source. MS detection was 
performed in positive ion mode, using selected reaction monitoring (SRM). The SRM transitions 
were set to 289 → 140 and 298 → 149 for bupivacaine and d9-bupivacaine respectively. In order 
to optimize the MS/MS parameters, a standard solution of bupivacaine was infused into the mass 
spectrometer. The following parameters were obtained.  Nitrogen was used for the sheath and 
auxiliary gases and was set at 50 and 15 arbitrary units. The HESI electrode was set to 3500 V 
and the capillary temperature was set to 350°C.  Argon was used as collision gas at a pressure of 
2.5 mTorr and the collision energy was set to 22 eV for bupivacaine and d9-bupivacaine. Total 
cycle time was set at 250 msec. Peak width of Q1 and Q3 were both set at 0.7 FWHM. 
Thermo Scientific Q-Exactive Plus Orbitrap Mass Spectrometer (San Jose, CA, USA) was 
interfaced with the UHPLC system using a pneumatic assisted heated electrospray ion source. 
MS detection was performed in positive ion mode but operating in scan mode at high-resolution, 
and accurate-mass (HR/AM). Identical source parameters were used. The scan range was set to 
m/z 100-500. Data was acquired at a resolving power of 70,000 (FWHM), resulting to a scanning 
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rate of  < 0.75 scans/sec when using automatic gain control target of 3.0x106 and maximum ion 
injection time of 100 msec. Post acquisition high resolution extracted ion chromatograms were 
generated using exact masse of targeted compounds ± 5 ppm. For comparison, please note that 
the QqQ instrument operated in a typical selected reaction monitoring (SRM) mode and the 
Quadrupole-Orbitrap mass spectrometer operated in scan HR/AM mode. The analytical range 
used was from 5 to 5 000 ng/mL and QC samples were prepared at concentrations of 5, 15, 250 
and 3000 ng/mL to test method precision and accuracy. Standards and QCs were prepared in cat 
EDTA plasma. The precision and accuracy were determined using three individual runs including 
six replicate of each QC level and a standard curve prepared independently for both instruments 
tested.   
Study samples 
Plasma samples from a previous pharmacokinetics (PK) study were used for comparison 
purposes [Benito et al. 2015]. Briefly, eight healthy adult female cats weighing 3.2 ± 0.7 kg were 
studied after owners’ written consent and institutional approval. General anesthesia was induced 
with propofol IV and maintained with isoflurane. Intraperitoneal bupivacaine 0.5% (2 mg kg-1) 
administration was performed and venous blood was drawn from the jugular vein (catheter 20G x 
2 mL) at 0, 2, 5, 10, 15, 20, 30, 60, 120 and 240 minutes after bupivacaine administration. Plasma 
bupivacaine concentrations were determined using QqQ instrument operating in SRM mode and 
a Quadrupole-Orbitrap mass spectrometer operating in scan HR/AM mode.  
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Data analysis and regression 
All regression analyses were performed with Prism (6.0f) GraphPad software (La Jolla, CA, 
USA) using the nonlinear curve-fitting module with an estimation of the goodness of fit. 
Statistical analyses and method comparison were also performed with Prism (6.0f).  
Results and Discussion 
Tandem Mass Spectrometry 
Precursor ion and product ion mass spectra for bupivacaine and d9-bupivacaine were obtained in 
positive ion mode. The precursor ion spectra of bupivacaine and d9-bupivacaine showed an 
intense signal for the protonated molecules ([M+H]+) at m/z 289.2 and m/z 298.3, respectively 
(Fig. 1A and Fig. 1B).  The product ion spectrum of bupivacaine and d9-bupivacaine has 
predominant fragment ions at m/z 140.0 and m/z 149.0 (Fig. 1C and Fig. 1D). The mass transition 
in SRM mode was set for best sensitivity and selectivity at m/z 289.2 → 140.0 and 298.3 → 
149.0 for bupivacaine and d9-bupivacaine respectively. The product ion spectra were compatible 
with the molecular structures. Quadrupole-Orbitrap HR/AM spectra (i.e 100 - 500 m/z) were 
acquired and protonated molecules ([M+H]+) at m/z 289.2268 and m/z 298.2832 were observed 
(Fig. 1E and Fig. 1D). The monoisotopic mass of bupivacaine (C18H29N2O+) is 289.2274 and d9-
bupivacaine (C18H20d9N2O+) is 298.2839. The observed masses are deviating by 2.1 ppm and 2.3 
ppm respectively which is within the instrument specifications. The high-resolution extracted ion 
chromatograms were generated using 289.2268 ± 5 ppm and m/z 298.2832 ± 5 ppm.  
Calibration Curve Analysis 
A linear regression (weighted 1/concentration) produced the best fit for the concentration–
detector relationship. The regression model used was determined using the sum of the squares of 
 9 
the deviations [Beaudry, 1999]. By convention, the regression line is considered to properly fit 
the calibration set when the sum of squares of the deviations is minimized. The concentrations 
were determined based on the peak area ratio of bupivacaine and its deuterated analogue d9-
bupivacaine. The calculated coefficients of correlation (r) were better than 0.9993 for an 
analytical range set from 5 to 5000 ng/mL in cat EDTA plasma. Both instrument provided 
equivalent linearity.  
 Precision and Accuracy 
The reproducibility of the method was evaluated by analyzing minimally six replicates of cat 
EDTA plasma fortified with bupivacaine at the nominal concentration of 5, 15, 250 and 3000 
ng/mL. The precision and accuracy results are displayed in Table 1. The precision and accuracy 
data presented using a QqQ instrument in SRM mode or a Quadrupole-Orbitrap mass 
spectrometer in full scan HR/AM mode and post acquisition extracted ion chromatograms 
provided equivalent results. Overall, the accuracy was ranging from 106.2 to 113.2% and the 
precision observed was from 1.0 to 3.7%. Thus, results obtained from both approaches 
demonstrated that acceptable precision and accuracy results were achieved and were compatible 
with generally accepted criteria in bioanalysis [CDER and CVM, 2001]. Representative 
chromatograms are shown in Fig 2. The LLOQ chromatograms reveal an intense signal in SRM 
mode using a QqQ instrument. The signal to noise ratio observed was ≈ 30 following analysis 
onto a Quadrupole-Orbitrap mass spectrometer in full scan HR/AM mode using post acquisition 
extracted ion chromatogram. Both approaches provided adequate sensitivity for our bupivacaine 
study, but there is a tradeoff in sensitivity when using Quadrupole-Orbitrap mass spectrometer in 
scan HR/AM mode. The LLOQ was set to 5 ng/mL for this method since all the study samples 
shown concentration well above the current 5 ng/mL. Indeed, the QqQ instrument in SRM mode 
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could be optimized to achieve a much lower LLOQ if required for a targeted pharmacokinetic 
assay. The Quadrupole-Orbitrap mass spectrometer was acquiring data at a high-resolution 
setting (70 000 FWHM) and the resulting scan rate was 0.75 sec/scan allowing the collection of 
sufficient data points to obtain reproducible quantitation based on peak area ratios (e.g. drug and 
internal standard). The resolution and resulting scan rate should be carefully chosen based on the 
chromatographic condition, particularly when using Ultra High Performance Liquid 
Chromatography (UHPLC) to assure adequate data sampling. The minimum number of data 
points for each chromatographic peak should be eight or above to reduce instrumental error. A 
careful assessment of instrument sensitivity is required to assure a good fit for purposes. As 
illustrated in Fig 2., extracted blank cat plasma samples did not show any interference from 
endogenous substances at the mass transition monitored (m/z 289.2 → 140.0) or at the post 
acquisition extracted ion chromatogram at m/z 289.2268 ± 5 ppm.  
Comparison of analytical methods 
Assessment of the equivalence in results generated by different analytical methodologies is 
important especially when methods are used in a regulated laboratory [Yoneyame et al., 2014]. 
This is particularly important in pharmaceutical sciences since a large proportion of the studies 
are conducted under GLP. Methodology changes are implemented for both scientific and 
technical reasons during a preclinical or clinical study. Thus, it is important to demonstrate the 
adequacy of using data generated by distinct methods as part of a single study. Study samples (n 
= 80) were extracted and analyzed using a QqQ instrument operating in SRM mode and a 
Quadrupole-Orbitrap mass spectrometer operating in full scan HR/AM mode. Using a linear 
regression, the analysis of paired measurements generated by both methods was assessed as 
shown in Fig. 3.  The linear regression quantifies goodness of fit and the R2 was 0.9996 and the 
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slope was 1.02 demonstrating a very strong correlation between both methods. Individual sample 
comparison showed differences from -4.5% to 1.6% well within the accepted analytical error 
[CDER and CVM, 2001]. The data demonstrated very good performance of the quantification 
method using HR/AM scan mode when compared to a state-of-the-art SRM assay. Targeted triple 
quadrupole SRM assays are very sensitive and quantitative, but they do not provide the benefit of 
comprehensive qualitative exploration or the possibility to re-visit data for further interrogation. 
Profiling samples using Quadrupole-Orbitrap mass spectrometer could allow the detection and 
confirmation of drug metabolites with high resolution and accurate mass.   
Profiling study samples 
The analysis of study samples using a Quadrupole-Orbitrap mass spectrometer in HR/AM scan 
mode allows scientists to extensively explore the resulting data. A majority of drugs have 
lipophilic properties and in most cases require biotransformation to be excreted [Yan and 
Caldwell, 2001]. Most biotransformation products result in a more polar substance and 
consequently are more easily excreted in urine and/or the biliary system. Hence the exposure of 
the animal (or human) to the compound is reduced and the potential toxicity may be reduced if 
the metabolites are pharmacologically inactive. The metabolic fate of a drug is an important 
factor contributing to its efficacy, toxicity, distribution and excretion. Metabolism is divided into 
two phases (i.e. phase 1 and phase 2). Phase 1 metabolic transformation includes oxidation, 
reduction and hydrolysis and phase 2 products are typically referred to as conjugated metabolites 
(i.e. glucuronide, sulphate, glutathione, cysteine, and methyl derivatives). Most of the metabolism 
is occurring in the liver because of its position, blood supply and function. However, other organs 
and tissues possess some metabolic activity and in some cases may be more important than the 
liver. As outlined before, biotransformation products often result in a change in mass that can be 
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predicted [Kostiainen et al., 2003]. Bupivacaine metabolism data are sparse and to our 
knowledge, no data were reported in cat. Two main metabolites were previously identified; 
desbutyl-bupivacaine and hydroxylated bupivacaine in other animal species [Pere et al., 1991; 
Gantenbein et al., 2000]. The monoisotopic mass of desbutyl-bupivacaine (C14H21N2O+) is m/z 
233.1648 and the monoisotopic mass of the hydroxylated bupivacaine (C18H29N2O2+) is m/z 
305.2224. As shown in Figure 4, post acquisition extracted ion chromatograms at m/z 233.1648 ± 
5 ppm (Fig. 4B) and m/z 305.2224 ± 5 ppm (Fig. 4C) revealed the presence of desbutyl-
bupivacaine and three distinct hydroxylated bupivacaine metabolites. Moreover, as illustrated in 
Figure 4, using targeted extracted ion chromatograms, we can concentration-time profiles for 
bupicavaine and its metabolites allowing semi-quantitative evaluations performed post 
acquisition. The metabolic fate of a drug is very important and the analysis of these cat samples 
permitted the identification of several metabolites with high accuracy and enabled the generation 
of concentration-time profiles that allowed us to better understand the drug elimination and 
exposition in a single injection without prior knowledge. High resolution and accurate mass 
acquisition strategies on high-resolution mass spectrometers permit data analysis that are not 
possible with SRM based method. These advanced acquisition strategies may have significant 
impacts in the development of quantitative and qualitative methods used in pharmaceutical drug 
discovery and development, clinical research and diagnostic, food safety, environmental analysis, 
forensic toxicology, and basic research. 
Conclusion 
Triple quadrupole mass spectrometers have been the workhorse for quantitative bioanalytical 
laboratories over the last two decades. It still delivers the best sensitivity and allows multiplexing 
using SRM mode. The introduction of high-resolution mass spectrometers driven for routine 
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analysis may modernize analytical strategies used in bioanalysis. These instruments have the 
sensitivity, speed, mass accuracy and resolution to deliver comprehensive qualitative and high-
resolution quantitation in complex biological matrices within a single injection. Moreover, data 
collected can be further analyzed as shown with the current example with the discovery of 
bupivacaine metabolites post sample analysis. We believe that the scope of high-resolution mass 
spectrometry in bioanalysis reaches far beyond the example shown in this paper and can enable 
analysis in pharmaceutical drug discovery and development, life science research, clinical 
research, toxicology and food and environmental safety that was not previously achievable using 
a single platform with a generic approach.  
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 Table 1. Determination of the precision and accuracy for the analysis of bupivacaine in feline 
plasma by HPLC-MS/SRM and HPLC-MS/HR/AM 
Instrumental Concentration   Intra (n=6)           Inter (n=18)       
Method (ng/mL)   Mean ± SD (ng/mL) % CV % NOM   Mean ± SD (ng/mL) % CV % NOM 
HPLC-
MS/SRM                           
 
5.00   5.60 ± 0.08 1.4 112.1   5.41 ± 0.16 3.0 108.1 
  15.0   16.3 ± 0.2 1.5 108.8   16.4 ± 0.3 1.6 109.2 
  250   276 ± 3 1.0 110.6   272 ± 5 1.9 108.9 
  3000   3211 ± 57 1.8 107.0   3245 ± 60 1.8 108.2 
HPLC-
MS/HR/AM                           
 
5.00   5.33 ± 0.12 2.2 106.6   5.31 ± 0.19 3.7 106.2 
  15.0   16.6 ± 0.4 2.3 110.4   16.4 ± 0.3 1.6 109.0 
  250   283 ± 3 1.0 113.2   276 ± 6 2.1 110.5 
  3000   3210 ± 38 1.2 107.0   3259 ± 53 1.6 108.6 
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Figure legends 
 
Figure 1. Positive mode ESI-MS and ESI-MS2 spectra of bupivacaine and d9-bupivacaine 
generated following a direct infusion on a triple quadrupole mass spectrometer and a hybrid 
quadrupole-orbitrap mass spectrometer. (A) and (B) are precursor ion spectra showing singly 
charged bupivacaine and d9-bupivacaine ions at m/z 289.2 and 298.0 obtained on a triple 
quadrupole mass spectrometer. (C) and (D) are product ion spectra generated by CID on a triple 
quadrupole mass spectrometer and subsequently used for the analysis in HPLC-MS/SRM mode. 
(E) and (F) are precursor ion spectra generated with a hybrid quadrupole-orbitrap mass 
spectrometer showing singly charged bupivacaine and d9-bupivacaine ions at m/z 289.2268 and 
298.2832 
Figure 2. Reconstructed ion chromatograms for bupivacaine. (A) HPLC-MS/SRM extracted ion 
chromatogram of transition m/z 289.2 → 140.0 of an extracted blank sample (red line), an 
extracted LLOQ plasma sample (blue line) and an extracted PK sample (green line). (B) HPLC-
MS/HR/AM extracted ion chromatogram of m/z 289.2268 (± 5 ppm) for an extracted blank 
sample (red line), an extracted LLOQ plasma sample (blue line) and an extracted PK sample 
(green line). 
Figure 3. Regression analysis for the assessment of the agreement between both mass 
spectrometric approaches for PK measurements. 
Figure 4. Overlay HPLC-MS/HR/AM extracted ion chromatograms for the drug and two 
metabolites. (A) Time overlays HPLC-MS/HR/AM extracted ion chromatograms for bupivacaine 
at m/z 289.2268 (± 5 ppm). (B) Time overlays HPLC-MS/HR/AM extracted ion chromatograms 
for desbutyl-bupivacaine at m/z 233.1648 (± 5 ppm). (C) Time overlays HPLC-MS/HR/AM 
extracted ion chromatograms for the hydroxylated bupivacaine at m/z 305.2224 (± 5 ppm). 
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